Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURANDOT: Bevacizumab + Paclitaxel vs Capecitabine in HER2- Breast Cancer
NCT00600340Phase 3Completed
- Sponsor
- Central European Cooperative Oncology Group
- Start
- Apr 2008
- Primary completion
- Sep 2014
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of capecitabine in breast cancer, sponsored by Central European Cooperative Oncology Group. Started Apr 2008; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00600340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00600340.